Cargando…
2896. Oral PrEP Uptake among HVTN 704/HPTN 085 Participants: Implications for the Future of Biomedical HIV Prevention Trials
BACKGROUND: The HVTN 704/HPTN 085 clinical trial (AMP study) assessed the efficacy of VRC01 broadly neutralizing antibody infusions for HIV prevention. It offered access to oral pre-exposure prophylaxis (PrEP) at no-cost to all participants as standard of HIV prevention care. Understanding PrEP init...
Autores principales: | Cantos, Valeria D, Neradilek, Moni, Gillespie, Kevin, Huang, Yunda, deCamp, Allan C, Karuna, Shelly T, Edupuganti, Srilatha, del Rio, Carlos, Veloso, Valdilea, Cohen, Myron S, Donnell, Deborah J, Corey, Lawrence, Roxby, Alison C, Kelley, Colleen F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677201/ http://dx.doi.org/10.1093/ofid/ofad500.167 |
Ejemplares similares
-
1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
por: Theodore, Deborah, et al.
Publicado: (2023) -
Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023) -
Draft Genome Sequence of the Freshwater Diatom Fragilaria crotonensis SAG 28.96
por: Zepernick, Brittany N., et al.
Publicado: (2022) -
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
por: Fuchs, Jonathan D., et al.
Publicado: (2015) -
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)